Avistone Biotechnology is a company focused on innovative drug development, particularly in the field of oncology. The company operates through its wholly-owned subsidiaries, Beijing Pearl Biotechnology Co., Ltd. and Beijing Avistone New Drug Technology Co., Ltd. Avistone is actively engaged in clinical studies targeting specific genetic mutations, such as the MET exon 14 mutation and primary MET amplification in non-small cell lung cancer (NSCLC). This focus on precision medicine highlights the company's commitment to developing targeted therapies that address the unique genetic profiles of cancer patients.

In addition to its research initiatives, Avistone has made significant strides in securing funding to support its development efforts. The company successfully completed a Series A funding round, raising over $200 million, which will aid in the advancement of its drug pipeline, including the MET inhibitor Vebreltinib. This drug is currently under review for the treatment of late-stage or metastatic NSCLC patients with specific genetic alterations. Avistone's innovative approach and strategic partnerships position it as a key player in the biotechnology sector, particularly in the development of precision cancer therapies.

China

Avistone is a commercial real estate investment firm specializing in the acquisition and management of multi-tenant industrial/warehouse properties. They focus on stabilized multi-tenant industrial properties and have a history of success achieving historical returns of 19.01%. Avistone was founded in 2013 and is rapidly growing in the commercial real estate investment industry.

Avistone

Company Details